Virus Shows Promise for Deep Tissue Imaging/Monitoring and Treating Pancreatic Cancer

    September 15, 2011

    In a press release issued Thursday by the American Association for Cancer Research (AACR), researchers announced that Genelux Corporation’s vaccinia virus, GLV-1h153, shows promise as a potential treatment and non-invasive deep tissue imaging modality for pancreatic cancer. Specifically, researchers have found that the

    • Virus construct may work to kill pancreatic cancer cells.
    • Therapeutic response to virus treatment can be noninvasively monitored.
    • Virus construct could facilitate targeted radiotherapy.

    The study is a collaboration between researchers at Memorial Sloan-Kettering Cancer Center in New York, N.Y., and at Genelux Corporation in San Diego, Calif. Study results were presented at the Second AACR International Conference on Frontiers in Basic Cancer Research, held Sept. 14-18, 2011, in San Francisco.

    To view the complete AACR press release, click here